Iralukast is a chemical compound classified as a leukotriene receptor antagonist, primarily used in the treatment of asthma and allergic rhinitis. It functions by inhibiting the action of leukotrienes, which are inflammatory mediators that contribute to bronchoconstriction and airway inflammation. The molecular structure of iralukast includes a specific arrangement of carbon, hydrogen, nitrogen, and oxygen atoms, which contributes to its pharmacological activity. It is typically administered orally and is known for its potential to improve lung function and reduce asthma symptoms. Iralukast has a favorable safety profile, although, like all medications, it may have side effects. Its mechanism of action makes it particularly useful in managing conditions where leukotriene pathways are implicated. As with any pharmaceutical agent, its use should be guided by a healthcare professional, considering individual patient needs and potential interactions with other medications.

iralukast

125617-94-9: Cgp 45715A, (S-(R*,S*-(E,Z)))-7-((9-(4-Acetyl-3-hydroxy-2-propylphenoxy)-1-(hydroxy(3-(trifluoromethyl)phenyl)methyl)-2,4-nonadienyl)thio)-4-oxo-4H-1-benzopyran-2-carboxylic acid monosodium salt, 1-Hydroxy-1-(3-trifluoromethylphenyl)-10-(4-acetyl-3-hydroxy-2-propylphenoxy)deca-3(E),5(Z)-diene-2-yl-7-thio-4-oxo-4H-1-benzopyran-2-carboxylic acid, Cgp-45715 A, 4H-1-Benzopyran-2-carboxylic acid, 7-((9-(4-acetyl-3-hydroxy-2-propylphenoxy)-1-(hydroxy(3-(trifluoromethyl)phenyl)methyl)-2,4-nonadienyl)thio)-4-oxo-, monosodium salt, (S-(R*,S*-(E,Z)))-, sodium 7-{[(1S,2E,4Z)-9-(4-acetyl-3-hydroxy-2-propylphenoxy)-1-{(R)-hydroxy[3-(trifluoromethyl)phenyl]methyl}nona-2,4-dien-1-yl]sulfanyl}-4-oxo-4H-chromene-2-carboxylate

CGP 45715A (irukostat) is a potent drug for respiratory diseases, blocking bronchial constriction and inflammation.

Cgp 45715A

Iralukast Na is a leukotriene receptor antagonist that prevents bronchoconstrictor response. It binds to the cystic fibrosis transmembrane conductance regulator (CFTR) and blocks the binding of leukotrienes, which are potent bronchoconstrictors. Iralukast Na also blocks the activity of inflammatory cells and reduces bowel inflammation. Iralukast Na has been shown to be effective in treating asthma, inflammatory bowel disease, and other autoimmune diseases.

CAS 125617-94-9: iralukast

Cgp 45715A

Ref: TM-T30835

Iralukast Na

Ref: 3D-FS104155